Erratum to: The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems (Topics in Medicinal Chemistry, 10.1007/7355_2013_29);The influence of bioisosteres in drug design: Tactical applications to address developability problems

Topics in Medicinal Chemistry

Volumn 9, Issue , 2014, Pages 283-382

  Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bioisostere; Carboxylic acid isosteres; Conformation; Drug water isostere; Guanidine and Amidine isosteres; Heterocyle isostere; Isostere; Phosphate isosteres

Indexed keywords

4' (2 BUTYL 4 CHLORO 5 HYDROXYMETHYL 1H IMIDAZOL 1 YLMETHYL) 2 BIPHENYLCARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA SECRETASE INHIBITOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BRADYKININ B1 RECEPTOR ANTAGONIST; CAPTOPRIL; CATHEPSIN K INHIBITOR; CATHEPSIN S INHIBITOR; CILUPREVIR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; EMTRICITABINE; FATTY ACID AMIDASE INHIBITOR; GAMMA SECRETASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; ILOPROST; INTEGRASE INHIBITOR; LAMIVUDINE; LEUKOCYTE ELASTASE INHIBITOR; LINEZOLID; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAVITOCLAX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ODANACATIB; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; UNINDEXED DRUG;

ACIDITY; ALKALINITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOISOSTERISM; CHEMICAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC50; LIPOPHILICITY; NONHUMAN; OSTEOPOROSIS; PROCESS OPTIMIZATION; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84916222761     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_74     Document Type: Erratum

References (395)

1. Burger A (1991) Isosterism and bioisosterism in drug design. Progress Drug Res 37:288–362
2. Patani GA, LaVoie EJ (1996) Bioisosterism: A rational approach in drug design. Chem Rev 96:3147–3176
3. Thornber CW (1979) Isosterism and molecular modification in drug design. Chem Soc Rev 8:563–580
4. Lipinski CA (1986) Bioisosterism in drug design. Ann Rep Med Chem 21:283–291
5. Wermuth CG, Bourguignon J-J (2003) In: Wermuth CG (ed) The practice of medicinal chemistry, 2nd edn. Chaps 12–16, Academic, London, pp 181–ISBN: 0-12-744640-0
6. Olsen PH (2001) The use of bioisosteric groups in lead optimization. Curr Opin Drug Discov Devel 4:471–478
7. Sheridan RP (2002) The most common chemical replacements in drug-like compounds. J Chem Inf Comput Sci 42:103–108
8. Wermuth CG (2005) Similarity in drugs: Reflections on analogue design. Drug Discov Today 11:348–354
9. Lima LM, Barriero EJ (2005) Bioisosterism: A useful strategy for molecular modification in drug design. Curr Med Chem 12:23–49
10. Meanwell NA (2011) Synopsis of some recent tactical applications of bioisosteres in drug design. J Med Chem 54:2529–2591
11. Langmuir I (1919) Isomorphism, isosterism and covalence. J Am Chem Soc 41:1543–1559
12. Erlenmeyer H, Berger E (1932) Studies on the significance of structure of antigens for the production and the specificity of antibodies. Biochem Z 252:22–36
13. Erlenmeyer H, Berger E, Leo M (1933) Relationship between the structure of antigens and the specificity of antibodies. Helv Chim Acta 16:733–738
14. Friedman HL (1951) Influence of isosteric replacements upon biological activity. NASNRS 206:295–358
15. Bégué J-P, Bonnet-Delpon D (2008) Bioorganic and medicinal chemistry of fluorine. Wiley, Hoboken
16. Böhm H-J, Banner D, Bendels S, Kansy M, Kuhn B, Müller K, Obst-Sander U, Stahl M (2004) Fluorine in medicinal chemistry. ChemBioChem 5:637–643
17. Müller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: Looking beyond intuition. Science 317:1881–1886
18. Hagman WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51:4359–4369
19. Shah P, Westwell AD (2007) The role of fluorine in medicinal chemistry. J Enzyme Inhib Med Chem 22:527–540
20. Purser S, Moore PR, Swallow S, Gouverneur V (2008) Fluorine in medicinal chemistry. Chem Soc Rev 37:320–330
21. O’Hagan D (2008) Understanding organofluorine chemistry. An introduction to the C–F bond. Chem Soc Rev 37:308–319
22. O’Hagan D (2010) Fluorine in health care: Organofluorine containing blockbuster drugs. J Fluorine Chem 131:1071–1081
23. Hodgetts KJ, Combs KJ, Elder AM, Harriman GC (2010) The role of fluorine in the discovery and optimization of CNS agents: Modulation of drug-like properties. Ann Rep Med Chem 45:429–448
24. Smart BE (2001) Fluorine substituent effects (on bioactivity). J Fluorine Chem 109:3–11
25. Schinazi RF, McMillan A, Cannon D, Mathis R, Loyd RM, Peck A, Sommadossi J-P, Clair M, Wilson J, Furman PA, Painter G, Choi W-B, Liotta DC (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5- fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36:2423–2431
26. Wang LH, Begley J, St. Claire RL, Harris J, Wakeford C, Rousseau FS (2004) Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Human Retroviruses 20:1173–1182
27. Feng JY, Shi J, Schinazi RF, Anderson KS (1999) Mechanistic studies show that (_) FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 13:1511–1517
28. Domagala JM, Hanna LD, Heifetz CL, Hutt MP, Mich TF, Sanchez JP, Solomon M (1986) New structure–activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J Med Chem 29:394–404
29. Barbachyn MR, Ford CW (2003) Oxazolidinone structure–activity relationships leading to linezolid. Angew Chem Int Ed 42:2010–2023
30. Meanwell NA, Wallace OB, Fang H, Wang H, Deshpande M, Wang T, Yin Z, Zhang Z, Pearce BC, James J, Yeung K-S, Qiu Z, Wright JJK, Yang Z, Zadjura L, Tweedie DL, Yeola S, Zhao F, Ranadive S, Robinson BA, Gong Y-F, Wang H-GH, Blair WS, Shi P-Y, Colonno RJ, P-f L (2009) Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorg Med Chem Lett 19:1977–1981
31. Kitas EA, Galley G, Jakob-Roetne R, Flohr A, Wostl W, Mauser H, Alker AM, Czech C, Ozmen L, David-Pierson P, Reinhardt D, Jacobsen H (2008) Substituted 2-oxo-azepane derivatives are potent, orally active γ-secretase inhibitors. Bioorg Med Chem Lett 18:304–308
32. Olsen JA, Banner DW, Seiler P, Wagner B, Tschopp T, Obst-Sander U, Kansy M, Müller K, Diederich F (2004) Fluorine interactions at the thrombin active site: Protein backbone fragments H-Cα-C¼O comprise a favorable C-F environment and interactions of C-F with electrophiles. ChemBioChem 5:666–675
33. Olsen JA, Banner DW, Seiler P, Sander UO, D’Arcy A, Stihle M, Muller K, Diederich F (2003) A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: Evidence for C-F•••C¼O interactions. Angew Chem Int Ed 42:2507–2511
34. Carini DJ, Christ DD, Duncia JV, Pierce ME (1989) The discovery and development of angiotensin II antagonists. Pharmaceutical Biotechnol 11:29–56
35. Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans PBMWM (1992) The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 12:149–191
36. Duncia JV, Chiu AT, Carini DJ, Gregory GB, Johnson AL, Price WA, Wells GJ, Wong PC, Calabrese JC, Timmermans PBMWM (1990) The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives. J Med Chem 33:1312–1329
37. Carini DJ, Duncia JV, Johnson AL, Chiu AT, Price WA, Wong PC, Timmermans PBMWM (1990) Nonpeptide angiotensin II receptor antagonists: N-[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives. J Med Chem 33:1330–1336
38. Carini DJ, Duncia JV, Aldrich PE, Chiu AT, Johnson AL, Pierce ME, Price WA, Santella JB III, Wells GJ, Wexler RR, Wong PC, Yoo S-E, Timmermans PBMWM (1991) Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem 34:2525–2547
39. Herr RJ (2002) 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry and synthetic methods. Bioorg Med Chem 10:3379–3393
40. Allen FH, Groom CR, Liebeschuetz JW, Bardwell DA, Olsson TSG, Wood PA (2012) The hydrogen bond environments of 1H-tetrazole and tetrazolate rings: The structural basis for tetrazole_carboxylic acid bioisosterism. J Chem Inf Model 52:857–866
41. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A, Karnik SS (1995) Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 270:2284–2289
42. Naylor EM, Chakravarty PK, Costello CA, Chang RS, Chen T-B, Faust KA, Lotti VJ, Kivlighn SD, Zingaro GJ, Siegl PKS, Wong PC, Carini DJ, Wexler RR, Patchett AA, Greenlee WJ (1993) Potent imidazole angiotensin II antagonists: Acyl sulfonamides and acyl sulfamides as tetrazole replacements. Bioorg Med Chem Lett 3:69–74
43. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Boes M, Cameron DR, Cartier M, Cordingley MG, Faucher A-M, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart M-A, Rancourt J, Sentjens RE, St. George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong C-L, Llinas-Brunet M (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186–189
44. Llinas-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher A-M, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maitre C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rheaume M, Tsantrizos YS, Lamarre D (2004) Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2J Med Chem 47:1605–1608
45. Stoltz JH, Stern JO, Huang Q, Seidler RW, Pack FD, Knight BL (2011) A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2Toxicol Pathol 39:496–501
46. Campbell JA, Good A (2002) Preparation of tripeptides as hepatitis C inhibitors. PCT Int. Appl. WO 2002/060,926
47. Scola PM, Sun L-Q, Chen J, Wang AX, Sit S-Y, Chen Y, D’Andrea SV, Zheng Z, Sin N, Venables BL, Cocuzza A, Bilder D, Carini D, Johnson B, Good AC, Rajamani R, Klei HE, Friborg J, Barry D, Levine S, Chen C, Sheaffer A, Hernandez D, Falk P, Yu F, Zhai G, Knipe JO, Mosure K, Shu Y-Z, Phillip T, Arora VK, Loy J, Adams S, Schartman R, Browning M, Levesque PC, Li D, Zhu JL, Sun H, Pilcher G, Bounous D, Lange RW, Pasquinelli C, Eley T, Colonno R, Meanwell NA, McPhee F (2010) Discovery of BMS-650032, an NS3 protease inhibitor for the treatment of Hepatitis C. In: 239th ACS national meeting and exposition, March 21–25, 2010, San Francisco. Abstract: MEDI-38
48. Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao S-S, McIntyre CJ, Nguyen KT, Romano JJ, Stahlhut M, Wan B-L, Olsen DB, Vacca JP (2008) Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J Am Chem Soc 130:4607–4609
49. Cummings MD, Lindberg J, Lin T-I, de Kock H, Lenz O, Lilja E, Fellander S, Baraznenok V, Nystrom S, Nilsson M, Vrang L, Edlund M, Rosenquist A, Samuelsson B, Raboisson P, Simmen K (2010) Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chemie Int Ed 49:1652–1655
50. Wendt MD (2008) Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction. Exp Opin Drug Discov 3:1123–1143
51. Petros AM, Dinges J, Augeri DA, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettesheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW (2006) Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 49:656–663
52. Park C-M, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X, Tahir SK, Tse C, Wang X, Wendt MD, Yang X, Zhang H, Fesik SW, Rosenberg SH, Elmore SW (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51:6902–6915
53. Laurence C, Berthelot M (2000) Observations on the strength of hydrogen bonding. Perspect Drug Discov Des 18:39–60
54. Laurence C, Brameld KA, Graton J, Le Questel J-Y, Renault E (2009) The pKBHX database: Toward a better understanding of hydrogen-bond basicity for medicinal chemists. J Med Chem 52:4073–4086
55. Abraham MH, Duce PP, Prior DV (1989) Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design. J Chem Soc Perkin Trans 2 1355–1375
56. Graton J, Berthelot M, Gal J-F, Laurence C, Lebreton J, Le Questel J-Y, Maria P-C, Robins R (2003) The nicotinic pharmacophore: Thermodynamics of the hydrogen-bonding complexation of nicotine, nornicotine, and models. J Org Chem 68:8208–8221
57. Arnaud V, Le Questel J-Y, Mathé-Allainmat M, Lebreton J, Berthelot M (2004) Multiple hydrogen-bond accepting capacities of polybasic molecules: the case of cotinine. J Phys Chem A 108:10740–10748
58. Locati A, Berthelot M, Evain M, Lebreton J, Le Questel J-Y, Mathé-Allainmat M, Planchat A, Renault E, Graton J (2007) The exceptional hydrogen-bond properties of neutral and protonated lobeline. J Phys Chem A 111:6397–6405
59. Arnaud V, Berthelot M, Evain M, Graton J, Le Questel J-Y (2007) Hydrogen-bond interactions of nicotine and acetylcholine salts: A combined crystallographic, spectroscopic, thermodynamic and theoretical study. Chem Eur J 13:1499–1510
60. Arnaud V, Berthelot M, Le Questel J-Y (2005) Hydrogen-bond accepting strength of protonated nicotine. J Phys Chem A 109:3767–3770
61. Arnaud V, Berthelot M, Felpin F-X, Lebreton J, Le Questel J-Y, Graton J (2009) Hydrogenbond accepting strength of five-membered N-heterocycles: The case of substituted phenylpyrrolines and myosmines. Eur J Org Chem 4939–4948
62. Graton J, Berthelot M, Gal J-F, Girard S, Laurence C, Lebreton J, Le Questel J-Y, Maria P-C, Naus P (2002) Site of protonation of nicotine and nornicotine in the gas phase: Pyridine or pyrrolidine nitrogen? J Am Chem Soc 124:10552–10562
63. Wermuth CG (2012) Are pyridazines privileged structures? Med Chem Commun 2:935–941
64. Taft RW, Anvia F, Taagpera M, Catalán J, Elguero J (1986) Electrostatic proximity effects in the relative basicities and acidities of pyrazole, imidazole, pyridazine, and pyrimidine. J Am Chem Soc 108:3237–3239
65. Meanwell NA, Romine JL, Seiler SM (1994) Non-prostanoid prostacyclin mimetics. Drugs Future 19:361–385
66. Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJK, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Zavoico GB, Seiler SM (1992) Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives. J Med Chem 35:3483–3497
67. Meanwell NA, Rosenfeld MJ, Wright JJK, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, Zavoico GB, Seiler SM (1993) Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted α- to the oxazole ring. J Med Chem 36:3871–3883
68. Meanwell NA, Romine JL, Rosenfeld MJ, Martin SW, Trehan AK, Wright JJK, Malley MF, Gougoutas JZ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, Zavoico GB, Seiler SM (1992) Nonprostanoid prostacyclin mimetics. 5. Structure– activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy] acetic acid. J Med Chem 36:3884–3903
69. Böhm H-J, Klebe G, Brode S, Hesse U (1996) Oxygen and nitrogen in competitive situations: which is the hydrogen-bond acceptor? Chem Eur J 2:1509–1513
70. Nobeli I, Price SL, Lommerse JPM, Taylor R (1997) Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles. J Comput Chem 18:2060–2074
71. Kumar DV, Rai R, Brameld KA, Riggs J, Somoza JR, Rajagopalan R, Janc JW, Xia YM, Ton TL, Hu H, Lehoux I, Ho JD, Young WB, Hart B, Green MJ (2012) 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. Bioorg Med Chem Lett 22:300–304
72. Boström J, Hogner A, Llinás A, Wellner E, Plowright AT (2012) Oxadiazoles in medicinal chemistry. J Med Chem 55:1817–1830
73. Jones ED, Vandegraaff N, Le G, Choi N, Issa W, MacFarlane K, Thienthong N, Winfield LJ, Coates JAV, Lu L, Li X, Feng X, Yu C, Rhodes DI, Deadman JJ (2010) Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold. Bioorg Med Chem Lett 20:5913–5917
74. Le G, Vandegraaff N, Rhodes DI, Jones ED, Coates JAV, Thienthong N, Winfield LJ, Lu L, Li X, Yu C, Feng X, Deadman JJ (2010) Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: azoles: Effective metal chelators. Bioorg Med Chem Lett 20:5909–5912
75. Le G, Vandegraaff N, Rhodes DI, Jones ED, Coates JAV, Lu L, Li X, Yu C, Feng X, Deadman JJ (2010) Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses. Bioorg Med Chem Lett 20:5013–5018
76. Johns BA, Weatherhead JG, Allen SH, Thompson JB, Garvey EP, Foster SA, Jeffrey JL, Miller WH (2009) The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 19:1802–1806
77. Johns BA, Weatherhead JG, Allen SH, Thompson JB, Garvey EP, Foster SA, Jeffrey JL, Miller WH (2009) 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. Bioorg Med Chem Lett 19:1807–1810
78. Kalgutkar AS, Jones R, Sawant A (2010) Sulfonamide as an essential functional group in drug design. In: Smith DA (ed) Metabolism, pharmacokinetics and toxicity of functional groups. RSC drug discovery series 1. Chap 5, Royal Society of Chemistry, London, pp 210–274
79. Hedstrom L (2002) Serine protease mechanism and specificity. Chem Rev 102:4501–4523
80. Long JZ, Cravatt BF (2011) The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev 111:6022–6063
81. Otrubova K, Boger DL (2012) α-Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH). ACS Chem Neurosci 3:340–348
82. Bradamante S, Pagani GA (1996) Benzyl and heteroarylmethyl carbanions: structure and substituent effects. Adv Carbanion Chem 2:189–263
83. Abbotto A, Bradamante S, Pagani GA (1993) Charge mapping in carbanions. Weak charge demand of the cyano group as assessed from a 13C-NMR study of carbanions of α-activated acetonitriles and phenylacetonitriles: Breakdown of a myth. J Org Chem 58:449–455
84. Abbotto A, Bradamante S, Pagani GA (1996) Diheteroarylmethanes. 5. E-Z isomerism of carbanions substituted by 1,3-azoles: 13C and 15N ð-charge/shift relationships as source for mapping charge and ranking the electron-withdrawing power of heterocycles. J Org Chem 61:1761–1769
85. Abbotto A, Bradamante S, Facchetti A, Pagani GA (1999) Diheteroarylmethanes. 8. Mapping charge and electron-withdrawing power of the 1,2,4-triazol-5-yl substituent. J Org Chem 64:6756–6763
86. Imperiali B, Abeles RH (1986) Inhibition of serine proteases by peptidyl fluoromethyl ketones. Biochemistry 25:3760–3767
87. Imperiali B, Abeles RH (1987) Extended binding inhibitors of chymotrypsin that interact with leaving group subsites S10–SBiochemistry 26:4474–4477
88. Edwards PD, Meyer EF Jr, Vijayalakshmi J, Tuthill PA, Andisik DA, Gomes B, Strimplerg A (1992) Elastase inhibitors, the peptidyl α-ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2- benzoxazole. J Am Chem Soc 114:1854–1863
89. Edwards PD, Wolanin DJ, Andisik DA, David MW (1995) Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. J Med Chem 38:76–85
90. Edwards P, Zottola MA, Davis M, Williams J, Tuthill PA (1995) Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl α-ketobenzoxazoles. J Med Chem 38:3972–3982
91. Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M (2000) Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem 43:4927–4929
92. Ohmoto K, Yamamoto T, Okuma M, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M, Cheronis JC, Spruce LW, Gyorkos A, Wieczorek M (2001) Development of orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem 44:1268–1285
93. Costanzo MJ, Almond HR Jr, Hecker LR, Schott MR, Yabut SC, Zhang H-C, Andrade- Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE (2005) In-depth study of tripeptide-based α-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1’ subsite and its implications to structure-based drug design. J Med Chem 48:1984–2008
94. Maryanoff BE, Costanzo MJ (2008) Inhibitors of proteases and amide hydrolases that employ α-ketoheterocycles as a key enabling functionality. Bioorg Med Chem 16:1562–1595
95. Romero FA, Hwang I, Boger DL (2006) Delineation of a fundamental α-ketoheterocycle substituent effect for use in the design of enzyme inhibitors. J Am Chem Soc 128:14004–14005
96. Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC (2009) Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 131:10497–10506
97. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CRW, Jorgensen WL, Cravatt BF (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849–1856
98. Hardouin C, Kelso MJ, Romero FA, Rayl TJ, Leung D, Hwang I, Cravatt BF, Boger DL (2007) Structure–activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem 50:3359–3368
99. DeMartino JK, Garfunkle J, Hochstatter DG, Cravatt BF, Boger DL (2008) Exploration of a fundamental substituent effect of α-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 18:5842–5846
100. Garfunkle J, Ezzili C, Ray TJ, Hochstatter DG, Hwang I, Boger DL (2008) Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 51:4392–4403
101. Mileni M, Garfunkle J, Ezzili C, Kimball FS, Cravatt BF, Stevens RC, Boger DL (2009) X-ray crystallographic analysis of α-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 53:230–240
102. Mileni M, Garfunkle J, Ezzili C, Cravatt BF, Stevens RC, Boger DL (2011) Fluoridemediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase. J Am Chem Soc 133:4092–4100
103. Otrubova K, Ezzili C, Boger DL (2011) The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 21:4674–4685
104. Hansch C, Leo A, Unger SH, Kim KH, Nikaitani D, Lien EJ (1973) Aromatic substituent constants for structure-activity correlations. J Med Chem 16:1207–1216
105. Cai J, Fradera X, van Zeeland M, Dempster M, Cameron KS, Bennett DJ, Robinson J, Popplestone L, Baugh M, Westwood P, Bruin J, Hamilton W, Kinghorn E, Long C, Uitdehaag JCM (2010) 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. Bioorg Med Chem Lett 20:4507–4510
106. Salonen LM, Holland MC, Kaib PSJ, Haap W, Benz J, Mary J-L, Kuster O, Schweizer WB, Banner DW, Diederich F (2012) Molecular recognition at the active site of factor Xa: cation–π interactions, stacking on planar peptide surfaces, and replacement of structural water. Chem Eur J 18:213–222
107. Harder M, Kuhn B, Diederich F (2013) Efficient stacking on protein amide fragments. ChemMedChem 8:397–404
108. Michel J, Tirado-Rives J, Jorgensen WL (2009) Energetics of displacing water molecules from protein binding sites: Consequences for ligand optimization. J Am Chem Soc 131:15403–15411
109. Lam PYS, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN, Chang C-H, Weber PC, Jackson DA, Sharpe TR, Erikson-Viitanen S (1994) Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380–384
110. Lam PYS, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang C-H, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Jackson DA, Erickson-Viitanen S, Hodge CN (1996) Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2’ structure–activity relationship, and molecular recognition of cyclic ureas. J Med Chem 39:3514–3525
111. De Lucca GV, Erickson-Viitanen S, Lam PYS (1997) Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule. Drug Discov Today 2:6–18
112. Nalam MNL, Peeters A, Jonckers TMH, Dierynck I, Schiffer CA (2007) Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol 81:9512–9518
113. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu X-H, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang L-Z, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. J Med Chem 45:4961–4974
114. Tikhe JG, Webber SE, Hostomsky Z, Maegley KA, Ekkers A, Li J, Yu X-H, Almassy RJ, Kumpf RA, Boritzki TJ, Zhang C, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang L-Z, Calvert AH, Golding BT, Griffin RJ, Newell DR (2004) Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-Ribose) polymerase. J Med Chem 47:5467–5481
115. García-Sosa AT, Firth-Clark S, Mancera RL (2005) Including tightly-bound water molecules in de novo drug design. Exemplification through in silico generation of poly(ADP-ribose) polymerase inhibitors. J Chem Inf Model 45:624–633
116. Chen JM, Xu SL, Wawrzak Z, Basarab GS, Jordan DB (1998) Structure-based design of potent inhibitors of scytalone dehydratase: Displacement of a water molecule from the active site. Biochemistry 37:17735–17744
117. Liu C, Wrobleski ST, Lin J, Ahmed G, Metzger A, Wityak J, Gillooly KM, Shuster DJ, McIntyre KW, Pitt S, Shen DR, Zhang RF, Zhang H, Doweyko AM, Diller D, Henderson I, Barrish JC, Dodd JH, Schieven GL, Leftheris K (2005) 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38α MAP kinase. J Med Chem 48:6261–6270
118. Wissner A, Berger DM, Boschelli DH, Floyd MB Jr, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou H-R, Upeslacis E, Wang YF, Wu B, Ye F, Zhang N (2000) 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem 43:3244–3256
119. Davies NGM, Browne H, Davis B, Drysdale MJ, Foloppe N, Geoffrey S, Gibbons B, Hart T, Hubbard R, Rugaard Jensen M, Mansell H, Massey A, Matassova N, Moore JD, Murray J, Pratt R, Ray S, Robertson A, Roughley SD, Schoepfer J, Scriven K, Simmonite H, Stokes S, Surgenor A, Webb P, Wood M, Wright L, Brough P (2012) Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. Bioorg Med Chem 20:6770–6789
120. Trujillo JI, Kiefer JR, Huang W, Day JE, Moon J, Jerome GM, Bono CP, Kornmeier CM, Williams ML, Kuhn C, Rennie GR, Wynne TA, Carron CP, Thorarensen A (2012) Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): A tale of two waters. Bioorg Med Chem Lett 22:2795–3799
121. Meanwell NA (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24:1420–1456
122. Johnson F (1968) Allylic strain in six membered rings. Acc Chem Res 68:375–413
123. Yamazaki T, Taguchi T, Ojima I (2009) Unique properties of fluorine and their relevance to medicinal chemistry and chemical biology. In: Ojima I (ed) Fluorine in medicinal chemistry and chemical biology. Chap 1, Wiley, Chichester, UK pp 1–46
124. Hunter L (2010) The C–F bond as a conformational tool in organic and biological chemistry. Beilstein J Org Chem 6. doi:10.3762/bjoc.6.38
125. Zimmer LE, Sparr C, Gilmour R (2011) Fluorine conformational effects in organocatalysis: An emerging strategy for molecular design. Angew Chem Int Ed 50:11860–11871
126. Buissonneaud DY, van Mourik T, O’Hagan D (2010) A DFT study on the origin of the fluorine gauche effect in substituted fluoroethanes. Tetrahedron 66:2196–2202
127. O’Hagan D (2012) Organofluorine chemistry: Synthesis and conformation of vicinal fluoromethylene motifs. J Org Chem 77:3689–3699
128. Wu D, Tian A, Sun H (1998) Conformational properties of 1,3-difluoropropane. J Chem Phys A 102:9901–9905
129. Tavasli M, O’Hagan D, Pearson C, Petty MC (2002) The fluorine gauche effect. Langmuir isotherms report the relative conformational stability of (±)-erythro- and (±)-threo-9,10- difluorostearic acids. Chem Commun 1226–1227
130. Hunter L, Kirsch P, Slawin AMZ, O’Hagan D (2009) Synthesis and structure of stereoisomeric multivicinal hexafluoroalkanes. Angew Chem Int Ed 48:5457–5460
131. Banks JW, Batsanov AS, Howard JAK, O’Hagan D, Rzepa H, Martin-Santamaria S (1999) The preferred conformation of α-fluoroamides. J Chem Soc Perkin 2:2409–2411
132. Briggs CRS, O’Hagan D, Howard JAK, Yulfi DS (2003) The C–F bond as a tool in the conformational control of amides. J Fluorine Chem 119:9–13
133. Dalvit D, Vulpetti A (2012) Intermolecular and intramolecular hydrogen bonds involving fluorine atoms: Implications for recognition, selectivity, and chemical properties. ChemMedChem 7:262–272
134. Schü ler M, O’Hagan D, Slawin AMZ (2005) The vicinal F-C-C-F moiety as a tool for influencing peptide conformation. Chem Commun 4324–4326
135. O’Hagan D, Rzepa HS, Schüler M, Slawin AMZ (2006) The vicinal difluoro motif: the synthesis and conformation of erythreo- and threo-diastereomers of 1,2-difluorodiphenylethanes, 2,3-difluorosuccinic acids and their derivatives. Beilstein J Org Chem 2. doi:10.1186/1860-5397-2-19
136. Winkler M, Moraux T, Khairy HA, Scott RH, Slawin AMZ, O’Hagan D (2009) Synthesis and vanilloid receptor (TRPV1) activity of the enantiomers of α-fluorinated capsaicin. ChemBioChem 10:823–828
137. Peddie V, Butcher RJ, Robinson WT, Wilce MCJ, Traore DAK, Abell AD (2012) Synthesis and conformation of fluorinated β-peptidic compounds. Chem Eur J 18:6655–6662
138. O’Hagan D, Bilton C, Howard JAK, Knight L, Tozer DJ (2001) The preferred conformation of N-β-fluoroethylamides. Observation of the fluorine amide gauche effect. J Chem Soc Perkin Trans 2:605–607
139. O’Hagan D, Rzepa HS (1997) Some influences of fluorine in bioorganic chemistry. Chem Commun 645–652
140. Mascitti V, Stevens BD, Choi C, McClure KF, Guimarães CRW, Farley KA, Munchhof MJ, Robinson RP, Futatsugi K, Lavergen SY, Lefker BA, Cornelius P, Bonin PD, Kalgutkar AS, Sharma R, Chen Y (2011) Design and evaluation of a 2(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. Bioorg Med Chem Lett 21:1306–1309
141. Holmgren SK, Taylor KM, Bretscher LE, Raines RT (1998) Code for collagen’s stability deciphered. Nature 392:666–667
142. Bretscher LE, Jenkins CL, Taylor KM, DeRider ML, Raines RT (2001) Conformational stability of collagen relies on a stereoelectronic effect. J Am Chem Soc 123:777–778
143. Hodges JA, Raines RT (2003) Stereoelectronic effects on collagen stability: the dichotomy of 4-fluoroproline diastereomers. J Am Chem Soc 125:9262–9263
144. Doi M, Nishi Y, Uchiyama S, Nisiuchi Y, Nakazawa T, Ohkubo T, Kobayasji Y (2003) Characterization of collagen model peptides containing 4-fluoroproline: (4(S)-fluoroproline- Pro-Gly)10 forms a triple helix, but (4(R)-fluoroproline-Pro-Gly)10 does not. J Am Chem Soc 125:9922–9923
145. Hodges JA, Raines RT (2005) Stereoelectronic and steric effects in the collagen triple helix: Toward a code for strand association. J Am Chem Soc 127:15923–15932
146. Shoulders MD, Kamer KJ, Raines RT (2009) Origin of the stability conferred upon collagen by fluorination. Bioorg Med Chem Lett 19:3859–3862
147. DeRider ML, Wilkins SJ, Waddell MJ, Bretscher LE, Weinhold F, Raines RT, Markley JL (2002) Collagen stability: Insights from NMR spectroscopic and hybrid density functional computational investigations of the effect of electronegative substituents on prolyl ring conformations. J Am Chem Soc 124:2497–2505
148. Doi M, Nishi Y, Kiritoshi N, Iwata T, Nago M, Nakano H, Uchiyama S, Nakazawa T, Wakamiya T, Kbayashi Y (2002) Simple and efficient syntheses of Boc- and Fmoc-protected 4(R)- and 4(S)-fluoroproline solely from 4(R)-hydroxyproline. Tetrahedron 58:8453–8459
149. Park S, Radmer RJ, Klein TE, Pande VS (2005) A new set of molecular mechanics parameters for hydroxyproline and its use in molecular dynamics simulations of collagenlike peptides. J Comput Chem 26:1612–1616
150. Kim W, Hardcastle KL, Conticello VP (2006) Fluoroproline flip-flop: regiochemcial reversal of a stereoelectronic effect on peptide and protein structures. Angew Chem Int Ed 45:8141–8814
151. Kitamoto T, Ozawa T, Abe M, Marubayashi S, Yamazaki T (2008) Incorporation of fluoroprolines to proctolin: Study on the effect of a fluorine atom towards peptidic conformation. J Fluorine Chem 129:286–293
152. Briggs CRS, Allen MJ, O’Hagan D, Tozer DJ, Slawin AMZ, Goeta AE, Howard JAK (2004) The observation of a large gauche preference when 2-fluoroethylamine and 2-fluoroethanol become protonated. Org Biomol Chem 2:732–740
153. Lankin DC, Chandrakumar NS, Rao SN, Spangler DP, Snyder JP (1993) Protonated 3-fluoropiperidines: An unusual fluoro directing effect and a test for quantitative theories of solvation. J Am Chem Soc 115:3356–3357
154. Snyder JP, Chandrakumar NS, Sato H, Lankin DC (2000) The unexpected diaxial orientation of cis-3,5-difluoropiperidine in water: A potent CF–NH charge-dipole effect. J Am Chem Soc 122:544–545
155. Sun A, Lankin DC, Harcastle K, Snyder JP (2005) 3-Fluoropiperidines and N-methyl-3- fluoropiperidinium salts: The persistence of axial fluorine. Chem Eur J 11:1579–1591
156. Deniau G, Slawin AMZ, Lebl T, Chorki F, Issberner JP, van Mourik T, Heygate JM, Lambert JJ, Etherington L-A, Sillar KT, O’Hagan D (2007) Synthesis, conformation and biological evaluation of the enantiomers of 3-fluoro-γ-aminobutyric acid ((R)- and (S)-3F-GABA): an analogue of the neurotransmitter GABA. ChemBioChem 8:2265–2274
157. Clift MD, Ji H, Deniau GP, O’Hagan D, Silverman RB (2007) Enantiomers of 4-amino-3- fluorobutanoic acid as substrates for γ-aminobutyric acid aminotransferase. Conformational probes for GABA binding. Biochemistry 46:13819–13828
158. Yamamoto I, Deniau GP, Gavande N, Chebib M, Johnston GAR, O’Hagan D (2011) Agonist responses of (R)- and (S)-3-fluoro-γ-aminobutyric acids suggest an enantiomeric fold for GABA binding to GABAC receptors. Chem Commun 47:7956–7958
159. Chia PW, Livesey MR, Slawin AMZ, van Mourik T, Wyllie DJA, O’Hagan D (2012) 3-Fluoro-N-methyl-D-asaprtic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors. Chem Eur J 18:8813–8819
160. Abraham RJ, Chambers EJ, Thomas AW (1994) Conformational analysis. Part An NMR and theoretical investigation of the gauche effect in fluoroethanols. J Chem Soc Perkin Trans 2:949–955
161. Abraham RJ, Smith TAD, Thomas AW (1996) Conformational analysis. Part OH-F hydrogen bonding and the conformation of trans-2-fluorocyclohexanol. J Chem Soc Perkin Trans 2:1949–1955
162. Myers AG, Barbay JK, Zhong B (2001) Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. J Am Chem Soc 123:7207–7219
163. Brameld KA, Kuhn B, Reuter DC, Stahl M (2008) Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis. J Chem Inf Model 48:1–24
164. Gomez R, Jolly S, Williams T, Tucker T, Tynebor R, Vacca J, McGaughey G, Lai M-T, Felock P, Munshi V, DeStefano D, Touch S, Miller M, Yan Y, Sanchez R, Liang Y, Paton B, Wan B-L, Anthony N (2011) Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase. Bioorg Med Chem Lett 21:7344–7350
165. Leroux F, Jeschke P, Schlosser M (2005) α-Fluorinated ethers, thioethers, and amines: anomerically biased species. Chem Rev 105:827–856
166. Massa MA, Spangler DP, Durley RC, Hickory BS, Connolly DT, Witherbee BJ, Smith ME, Sikorski JA (2001) Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesterol ester transfer protein. Bioorg Med Chem Lett 11:1625–1628
167. Horne DB, Bartberger MD, Kaller MR, Monenschein H, Zhong W, Hitchcock SA (2009) Synthesis and conformational analysis of α, α-difluoroalkyl heteroaryl ethers. Tetrahedron Lett 50:5452–5455
168. Anderson GM III, Kollman PA, Domelsmith LN, Houk KN (1979) Methoxy group nonplanarity in o-dimethoxybenzenes. Simple predictive models for conformations and rotational barriers in alkoxyaromatics. J Am Chem Soc 101:2344–2352
169. Klocker J, Karpfen A, Wolschann P (2003) On the structure and torsional potential of trifluoromethoxybenzene: An ab initio and density functional study. Chem Phys Lett 367:566–575
170. Chien RJ, Corey EJ (2010) Strong conformational preferences of heteroaromatic ethers and electron pair repulsion. Org Lett 12:132–135
171. Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM (1998) Discovery of N-[2-[5-[amino(imino)methyl]-2- hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy] pyridin-4-yl]-N-methylglycine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J Med Chem 41:3557–3562
172. Phillips G, Davey DD, Eagen KA, Koovakkat SK, Liang A, Ng HP, Pinkerton M, Trinh L, Whitlow M, Beatty AM, Morrissey MM (1999) Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J Med Chem 42:1749–1756
173. Adler M, Davey DD, Phillips GB, Kim S-H, Jancarik J, Rumennik G, Light DR, Whitlow M (2000) Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry 39:12534–12542
174. Chen YL, Mansbach RS, Winter SM, Brooks E, Collins J, Michael L. Corman ML, Dunaiskis AR, Faraci WS, Gallaschun RJ, Schmidt A, Schulz DW (1997) Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor-1 receptor antagonist. J Med Chem 40:1749–1754
175. Semple G, Lehmann J, Wong A, Ren A, Bruce M, Shin Y-J, Sage CR, Morgan M, Chen W-C, Sebring K, Chu Z-L, Leonard JN, Al-Shamma H, Grottick AJ, Du F, Liang Y, Demarest K, Jones RM (2012) Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett 22:1750–1755
176. Qiao JX, Cheney DL, Alexander RS, Smallwood AM, King SR, He K, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PYS (2008) Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of factor Xa. Bioorg Med Chem Lett 18:4118–4123
177. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision making in medicinal chemistry. Nat Rev Drug Discov 6:881–890
178. Tarcsay A, Nyíri K, Keserű GM (2012) Impact of lipophilic efficiency on compound quality. J Med Chem 55:1252–1260
179. Keserű GM, Makara GM (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8:203–212
180. Hann M, Keserű GM (2012) Finding the sweet spot: The role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 11:355–365
181. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: Increasing saturation as an approach to improving clinical success. J Med Chem 52:6752–6756
182. Lovering F (2013) Escape from flatland 2: Complexity and promiscuity. Med Chem Commun 4:515–519
183. Pellicciari R, Raimondo M, Marinozzi M, Natalini B, Costantino G, Thomsen C (1996) (S)-(+)-2-(3’-Carboxybicyclo[1.1.1]pentyl)glycine, a structurally new group 1 metabotropic glutamate receptor antagonist. J Med Chem 39:2874–2876
184. Pellicciari R, Costantino G, Giovagnoni E, Mattoli L, Brabet I, Pin J-P (1998) Synthesis and preliminary evaluation of (S)-2-(4’-carboxycubyl)glycine, a new selective mGluR1 antagonist. Bioorg Med Chem Lett 8:1569–1574
185. Costantino G, Maltoni K, Marinozzi M, Camaioni E, Prezeau L, Pin J-P, Pellicciari R (2001) Synthesis and biological evaluation of 2-(3’-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. Bioorg Med Chem 9:221–227
186. Stepan AF, Subramanyam C, Efremov IV, Dutra JK, O’Sullivan TJ, DiRico KJ, McDonald WS, Won A, Dorff PH, Nolan CE, Becker SL, Pustilnik LR, Riddell DR, Kauffman GW, Kormos BL, Zhang L, Lu Y, Capetta SH, Green ME, Karki K, Sibley E, Atchison KP, Hallgren AJ, Oborski CE, Robshaw AE, Sneed B, O’Donnell CJ (2012) Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor. J Med Chem 55:3414–3424
187. Pinto DJP, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PYS (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro- 20-(methylsulfonyl)-[1,10-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566–578
188. Quan ML, Lam PYS, Han Q, Pinto DJP, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun J-H, Alexander RS, Bai S, Luettgen JM, Knabb RM, WongPC, WexlerRR(2005) Discovery of 1-(30-aminobenzisoxazol-50-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(20-dimethylaminomethyl) imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 48:1729–1744
189. Nayak SK, Reddy MK, Guru Row TN, Chopra D (2011) Role of hetero-halogen (F. . ..X, X ¼ Cl, Br, and I) or homo-halogen (X. . .X, X ¼ F, Cl, Br, and I) interactions in substituted benzanilides. Crystal Growth Des 11:1578–1596
190. Chopra D, Row TNG (2008) Evaluation of the interchangeability of C–H and C–F groups: insights from crystal packing in a series of isomeric fluorinated benzanilides. Cryst Eng Comm 10:54–67
191. Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, Semus SF, Evans C, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D (2008) Potent, selective and orally bioavailable dihydropyrimidine inhibitors of rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem 51:6631–6634
192. Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LL, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol- 4-yl)phenyl)-N0-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584–1597
193. Weiss MM, Williamson T, Babu-Khan S, Bartberger MD, Brown J, Chen K, Cheng Y, Citron M, Croghan MD, Dineen TA, Esmay J, Graceffa RF, Harried SS, Hickman D, Hitchcock SA, Horne DB, Huang H, Imbeah-Ampiah R, Judd T, Kaller MR, Kreiman CR, La DS, Li V. Lopez P, Louie S, Monenschein H, Nguyen TT, Pennington LD, Rattan C, San Miguel T, Sickmier EA, Wahl RC, Wen PH, Wood S, Xue Q, Yang BH, Patel VF, Zhong W (2012) Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. J Med Chem 55:9009–9024
194. Dineen TA, Weiss MM, Williamson T, Acton P, Babu-Khan S, Bartberger MD, Brown J, Chen K, Cheng Y, Citron M, Croghan MD, Dunn RT, Esmay J, Graceffa RF, Harried SS, Hickman D, Hitchcock SA, Horne DB, Huang H, Imbeah-Ampiah R, Judd T, Kaller MR, Kreiman CR, La DS, Li V, Lopez P, Louie S, Monenschein H, Nguyen TT, Pennington LD, San Miguel T, Sickmier EA, Vargas HM, Wahl RC, Wen PH, Whittington DA, Wood S, Xue Q, Yang BH, Patel VF, Zhong W (2012) Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem 55:9025–9044
195. Kaller MR, Harried SS, Albrecht B, Amarante P, Babu-Khan S, Bartberger MD, Brown J, Brown R, Chen K, Cheng Y, Citron M, Croghan MD, Graceffa R, Hickman D, Judd T, Kriemen C, La D, Li V, Lopez P, Luo Y, Masse C, Monenschein H, Nguyen T, Pennington LD, Miguel TS, Sickmier EA, Wahl RC, Weiss MM, Wen PH, Williamson T, Wood S, Xue M, Yang B, Zhang J, Patel V, Zhong W, Hitchcock S (2012) A potent and orally efficacious, hydroxyethylamine-based inhibitor of β-secretase. ACS Med Chem Lett 3:886–891
196. Hitchcock SA (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds. J Med Chem 55:4877–4895
197. Desai PV, Raub TJ, Blanco M-J (2012) How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg Med Chem Lett 22:6540–6548
198. Kuduk SD, Di Marco CN, Chang RK, Wood MR, Schirripa KM, Kim JJ, Wai JMC, DiPardo RM, Murphy KL, Ransom RW, Harrell CM, Reiss DR, Holahan MA, Cook J, Hess JF, Sain N, Urban MO, Tang C, Prueksaritanont T, Pettibone DJ, Bock MG (2007) Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. J Med Chem 50:272–282
199. Ettorre E, D’Andrea P, Mauro S, Porcelloni M, Rossi C, Altamura M, Catalioto RM, Giuliani S, Maggi CA, Fattori D (2011) hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. Bioorg Med Chem Lett 21:1807–1809
200. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen C, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790
201. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J (2010) Structure– activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53:2779–2796
202. Marsham PR, Wardleworth JM, Boyle FT, Hennequin LF, Kimbell R, Brown M, Jackman AL (1999) Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J Med Chem 42:3809–3820
203. Niculesco-Duvaz I (2000) ZD-9331 (Astra-Zeneca). Curr Opin Investig Drugs 1:141–149
204. Swahn B-M, Kolmodin K, Karlstroem S, von Berg S, Soederman P, Holenz J, Berg S, Lindstroem J, Sundstroem M, Turek D, Kihlstroem J, Slivo C, Andersson L, Pyring D, Rotticci D, Oehberg L, Kers A, Bogar K, Bergh M, Olsson L-L, Janson J, Eketjaell S, Georgievska B, Jeppsson F, Faelting J (2012) Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem 55:9346–9361
205. Peterlin-Mašič L, Kikelj D (2001) Arginine mimetics. Tetrahedron 57:7073–7105
206. Peterlin-Mašič L (2006) Arginine mimetic structure in biologically active antagonists and inhibitors. Curr Med Chem 13:3627–3648
207. Pinto DJP, Smallheer JM, Cheney DL, Knabb RM, Wexler RR (2010) Factor Xa inhibitors: next generation antithrombotic agents. J Med Chem 53:6243–6274
208. Danalev D (2012) Inhibitors of serine proteinases from blood coagulation cascade – view on current developments. Mini Rev Med Chem 12:721–730
209. Nar H (2012) The role of structural information in the discovery of direct thrombin and factor Xa inhibitors. Trends Pharmacol Sci 33:279–288
210. Srivastave S, Goswami LN, Dikshit DK (2005) Progress in the design of low molecular weight thrombin inhibitors. Med Res Rev 25:66–92
211. Ghorai P, Kraus A, Keller M, Gotte C, Igel P, Schneider E, Schnell D, Bernhardt G, Dove S, Zabel M, Elz S, Seifert R, Buschauer A (2008) Acylguanidines as bioisosteres of guanidines: NG-acylated Imidazolylpropylguanidines, a new class of histamine H2 receptor agonists. J Med Chem 51:7193–7204
212. Kraus A, Ghorai P, Birnkammer T, Schnell D, Elz S, Seifert R, Dove S, Bernhardt G, Buschauer A (2009) NG-acylated aminothiazolylpropylguanidines as potent and selective histamine H2 receptor agonists. ChemMedChem 4:232–240
213. Pluym N, Brennauer A, Keller M, Ziemek R, Pop N, Bernhardt G, Buschauer A (2011) Application of the guanidine–acylguanidine bioisosteric approach to argininamide-type NPY Y2 receptor antagonists. ChemMedChem 6:1727–1738
214. Tomczuk B, Lu T, Soll RM, Fedde C, Wang A, Murphy L, Crysler C, Dasgupta M, Eisennagel S, Spurlino J, Bone R (2003) Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. Bioorg Med Chem Lett 13:1495–1498
215. Lu T, Markotan T, Coppo F, Tomczuk B, Crysler C, Eisennagel S, Spurlino J, Gremminger L, Soll RM, Giardino EC, Bone R (2004) Oxyguanidines. Part 2: discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. Bioorg Med Chem Lett 14:3727–3731
216. Lee L, Kreutter KD, Pan W, Crysler C, Spurlino J, Player MR, Tomczuk B, Lu T (2007) 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. Bioorg Med Chem Lett 17:6266–6269
217. Kreutter KD, Lu T, Lee L, Giardino EC, Patel S, Huang H, Xu G, Fitzgerald M, Haertlein BJ, Mohan V, Crysler C, Eisennagel S, Dasgupta M, McMillan M, Spurlino JC, Huebert ND, Maryanoff BE, Tomczuk BE, Damiano BP, Player MR (2008) Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. Bioorg Med Chem Lett 18:2865–2870
218. Lu T, Markotan T, Ballentine SK, Giardino EC, Spurlino J, Brown K, Maryanoff BE, Tomczuk BE, Damiano BP, Shukla U, End D, Andrade-Gordon P, Bone RF, Player MR (2010) Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino} carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. J Med Chem 53:1843–1856
219. Lam PYS, Clark CG, Li R, Pinto DJP, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR (2003) Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J Med Chem 46:4405–4418
220. Pinto DJP, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PYS (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl]phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339–5356
221. Rye CS, Baell JB (2005) Phosphate isosteres in medicinal chemistry. Curr Med Chem 12:3127–3141
222. Romanenko VD, Kukhar VP (2006) Fluorinated phosphonates: synthesis and biomedical application. Chem Rev 106:3868–3935
223. Elliott TS, Slowey A, Yeb Y, Conway SJ (2012) The use of phosphate bioisosteres in medicinal chemistry and chemical biology. Med Chem Commun 3:735–751
224. Blackburn GM, Kent DE (1981) A novel synthesis of α- and γ-fluoroalkylphosphonates. JCS Chem Comm 511–513
225. Blackburn GM, England DA, Kolkmann F (1981) Monofluoro- and difluoromethylenebisphosphonic acids : isopolar analogues of pyrophosphoric acid. JCS Chem Comm 930–932
226. Smyth MS, Ford H Jr, Burke TR Jr (1992) A general method for the preparation of benzylic α, α-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine. Tet Lett 33:4137–4140
227. Hecker SJ, Erion MD (2008) Prodrugs of phosphates and phosphonates. J Med Chem 51:2328–2345
228. Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82:A84–A98
229. Pertusati F, Serpi M, McGuigan C (2012) Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antiviral Chem Chemother 22:181–203
230. Combs AP (2007) Structure-based drug design of new leads for phosphatase research. IDrugs 10:112–115
231. Combs AP (2010) Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 53:2333–2344
232. Savarino A (2006) A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Exp Opin Investig Drugs 15:1507–1522
233. Johns BA, Svolto AC (2008) Advances in two-metal chelation inhibitors of HIV integrase. Exp Opin Ther Patents 18:1225–1237
234. Ramkumar K, Serrao E, Odde S, Neamati N (2010) HIV-1 integrase inhibitors: 2007–2008 update. Med Res Rev 30:890–954
235. Pendri A, Meanwell NA, Peese KM, Walker MA (2011) New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Exp Opin Ther Patents 21:1173–1189
236. Ingale KB, Bhatia MS (2011) HIV-1 integrase inhibitors: a review of their chemical development. Antiviral Chem Chemother 22:95–105
237. Beare KD, Coster MJ, Rutledge PJ (2012) Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond. Curr Med Chem 19:1177–1192
238. Leeson PD, St-Gallay SA, Wenlock MC (2011) Impact of ion class and time on oral drug molecular properties. Med Chem Commun 2:91–105
239. Manallack DT, Prankerd RJ, Yuriev E, Oprea TI, Chalmers DK (2013) The significance of acid/base properties in drug discovery. Chem Soc Rev 42:485–496
240. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, Bender A, Jenkins JL, Urban L (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2:874–880
241. Peters J-E, Schnider P, Mattei P, Kansy M (2009) Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4:680–686
242. Waring MJ, Johnstone C (2007) A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg Med Chem Lett 17:1759–1764
243. Jamieson C, Moir EM, Rankovic Z, Wishart G (2006) Medicinal chemistry of hERG optimizations: highlights and hang-ups. J Med Chem 49:5029–5046
244. Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, Adams SP (2010) Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem Res Toxicol 23:749–755
245. Ratcliffe AJ (2009) Medicinal chemistry strategies to minimize phospholipidosis. Curr Med Chem 16:2816–2823
246. Bernstein PR, Ciaccio P, Morelli J (2011) Drug-induced phospholipidosis. Ann Rep Med Chem 46:419–430
247. Morgenthaler M, Schweizer E, Hoffman-Röder A, Benini F, Martin RE, Jaeschke G, Wagner B, Fischer H, Bendels S, Zimmeli D, Scheider J, Diedeich F, Kansy M, Müller K (2007) Predicting and tuning physicochemical properties in led optimization: aminebasicities. ChemMedChem 2:1100–1115
248. Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD (2008) Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem 51:4239–4252
249. Kalgutkar AS, Obach RS, Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–447
250. Goncharov NV, Jenkins RO, Radilov AS (2006) Toxicology of fluoroacetate: a review, with possible directions for therapy research. J Appl Toxicol 26:148–161
251. Sani M, Volonterio A, Zanda M (2007) The trifluoroethylamine function as peptide bond replacement. ChemMedChem 2:1693–1700
252. Zanda M (2004) Trifluoromethyl group: an effective xenobiotic function for peptide backbone modification. New J Chem 28:1401–1411
253. Molteni M, Pesenti C, Sani M, Volonterio A, Zanda M (2004) Fluorinated peptidomimetics: synthesis, conformational and biological features. J Fluorine Chem 125:1735–1743
254. Molteni M, Bellucci MC, Bigotti S, Mazzini S, Volonterio A, Zanda M (2009) Ψ[CH(CF3) NH]Gly-peptides: synthesis and conformation analysis. Org Biomol Chem 7:2286–2296
255. Black WC, Bayly C, Davis DE, Desmarais S, Falgueyret J-P, Leger S, Li CS, Masse F, McKay DJ, Palmer JT, Percival MD, Robichaud J, Tsou N, Zamboni R (2005) Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. Bioorg Med Chem Lett 15:4741–4744.
256. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret J-P, Kimmel DB, Lamontagne S, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Therien M, Truong V-L, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923–928.
257. Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, Da Silva C, Rosenberg E, Leung A (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Mineral Res 27:2251–2258.
258. Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuers T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580.
259. Ng KW (2012) Potential role of odanacatib in the treatment of osteoporosis. Clin Intervent Aging 7:235–247.
260. Isabel E, Mellon C, Boyd MJ, Chauret N, Deschênes D, Desmarais S, Falgueyret J-P, Gauthier JY, Khougaz K, Lau CK, Léger S, Levorse DA, Li CS, Massé F, Percival MD, Roy B, Scheigetz J, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC (2011) Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. Bioorg Med Chem Lett 21:920–923.
261. Grunewald GL, Seim MR, Lu J, Makboul M, Criscione KR (2006) Application of the Goldilocks effect to the design of potent and selective inhibitors of phenylethanolamine Nmethyltransferase: balancing pKa and steric effects in the optimization of 3-methyl-1,2,3,4- tetrahydroisoquinoline inhibitors by α-fluorination. J Med Chem 49:2939–2952.
262. Wuitschik G, Rogers-Evans M, Müller K, Fischer H, Wagner B, Schuler F, Polonchuk L, Carreira EM (2006) Oxetanes as promising modules in drug discovery. Angew Chem Int Ed 45:7736–7739.
263. Wuitschik G, Rogers-Evans M, Buckl A, Bernasconi M, Marki M, Godel T, Fischer H, Wagner B, Parrilla I, Schuler F, Schneider J, Alker A, Schweizer WB, Müller K, Carreira EM (2008) Spirocyclic oxetanes: synthesis and properties. Angew Chem Int Ed 47:4512–4515.
264. Wuitschik G, Carreira EM, Wagner B, Fischer H, Parrilla I, Schuler F, Rogers-Evans M, Müller K (2010) Oxetanes in drug discovery: structural and synthetic insights. J Med Chem 53:3227–3246.
265. Burkhard JA, Wuitschik G, Rogers-Evans M, Müller K, Carreira EM (2010) Oxetanes as versatile elements in drug discovery and synthesis. Angew Chem Int Ed 49:9052–9067.
266. Jung ME, Piizzi G (2005) gem-Disubstituent effect: Theoretical basis and synthetic applications. Chem Rev 105:1735–1766.
267. Freire E (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13:869–874.
268. Ladbury JE, Klebe G, Freire E (2010) Adding calorimetric data to decision making in lead discovery: A hot tip. Nat Rev Drug Discov 9:23–27.
269. Lafont V, Armstrong AA, Ohtaka H, Kiso Y, Amzel LM, Freire E (2007) Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Des 69:413–422.
270. Freire E (2009) A thermodynamic approach to the affinity optimization of drug candidates. Chem Biol Drug Des 74:468–472.
271. Hann MM (2011) Molecular obesity, potency and other addictions in drug discovery. Med Chem Commun 2:349–355.
272. Tarcsay A, Keseru˝ GM (2013) Contributions of molecular properties to drug promiscuity. J Med Chem 56:1789–1795.
273. Ritchie TR, Macdonald SJF (2009) The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 14:1011–1020.
274. Ritchie TR, Macdonald SJF, Young RJ, Pickett SD (2011) The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today 16:164–171.
275. Ritchie TJ, Macdonald SJF, Peace S, Pickett SD, Luscombe CN (2012) The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others? Med Chem Commun 3:1062–1069.
276. Brown A, Brown TB, Calabrese A, Ellis D, Puhalo N, Ralph M, Watson L (2010) Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent. Bioorg Med Chem Lett 20:516–520.
277. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K, Iwama T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Iwasawa Y, Hayama T, Nishimura S, Morishima H (2001) Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 44:4615–4627.
278. Furet P, Caravatti G, Guagnano V, Lang M., Meyer T, Schoepfer J (2008) Entry into a new class of protein kinase inhibitors by pseudo ring design. Bioorg Med Chem Lett 18:897–900.
279. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Graus Porta D (2012) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1- {6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 54:7066–7083.
280. Furet P, Bold G, Hofmann F, Manley P, Meyer T, Altmann K-H (2003) Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg Med Chem Lett 13:2967–2971.
281. Liu KKC, Huang X, Bagrodia S, Chen JH, Greasley S, Cheng H, Sun S, Knighton D, Rodgers C, Kristina Rafidi K, Zou A, Xiao J, Yan S (2011) Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett 21:1270–1274.
282. Zhang G, Ren P, Gray NS, Sim T, Liu Y, Wang X, Che J, Tians-s SML, Spalding TA, Romeo R, Iskandar M, Chow D, Seidel HM, Karanewsky DS, He Y (2008) Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I. Bioorg Med Chem Lett 18:5618–5621.
283. Wan Z, Boehm JC, Bower MJ, Kassis S, Lee JC, Zhao B, Adams JL (2003) N-Phenyl-Npurin- 6-yl ureas: the design and synthesis of P38α MAP kinase inhibitors. Bioorg Med Chem Lett 13:1191–1194.
284. Jansma A, Zhang Q, Li B, Ding Q, Uno T, Bursulaya B, Liu Y, Furet P, Gray NS, Geierstanger BH (2007) Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy. J Med Chem 50:5875–5877.
285. Kuhn B, Mohr P, Stahl M (2010) Intramolecular hydrogen bonding in medicinal chemistry. J Med Chem 53:2601–2611.
286. Mathieu S, Gradl SN, Ren L, Wen Z, Aliagas I, Gunzner-Toste J, Lee W, Pulk R, Zhao G, Alicke B, Boggs JW, Buckmelter AJ, Choo EF, Dinkel V, Gloor SL, Gould SE, Hansen JD, Hastings G, Hatzivassiliou G, Laird ER, Moreno D, Ran Y, Voegtli WC, Wenglowsky S, Grina J, Rudolph J (2012) Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties. J Med Chem 55:2869–2881.
287. Larsen AA, Lish PM (1964) A new bioisostere: alkylsulphonamidophenethanolamines. Nature 203:1283–1284.
288. Hitchcock SA, Pennington LD (2006) Structure–brain exposure relationships. J Med Chem 49:7559–7583.
289. Nirogi RVS, Daulatabad AV, Parandhama G, Mohammad S, Sastri KR, Shinde AK, Dubey PK (2010) Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT6 receptor antagonists. Bioorg Med Chem Lett 20:4440–4443.
290. Ahmed M, Briggs MA, Bromidge SM, Buck T, Campbell L, Deeks NJ, Garner A, Gordon L, Hamprecht DW, Holland V, Johnson CN, Medhurst AD, Mitchell DJ, Moss SF, Powles J, Seal JT, Stean TO, Stemp G, Thompson M, Trail B, Upton N, Winborn K, Witty DR (2005) Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. Bioorg Med Chem Lett 15:4867–4871.
291. Zhao S-H, Berger J, Clark RD, Sethofer SG, Krauss NE, Brothers JM, Martin RS, Misner DL, Schwab AL (2007) 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett 17:3504–3507.
292. Nirogi R, Shinde A, Daulatabad A, Kambhampati R, Gudla P, Shaik M, Gampa M, Balasubramaniam S, Gangadasari P, Reballi V, Badange R, Bojja K, Subramanian R, Bhyrapuneni G, Muddana N, Jayarajan P (2012) Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT6 receptor antagonists. J Med Chem 55:9255–9269.
293. Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A (2012) CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups. Bioorg Med Chem Lett 22:2894–2897.
294. Fulp A, Bortoff K, Zhang Y, Seltzman H, Snyder R, Maitra R (2011) Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorg Med Chem Lett 21:5711–5714.
295. Burgey CS, Robinson KA, Lyle TA, Sanderson PEJ, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C, White RB, Wong B, Lyle EA, Williams PD, Coburn CA, Dorsey BD, Barrow JC, Stranieri MT, Holahan MA, Sitko GR, Cook JJ, McMasters DR, McDonough CM, Sanders WM, Wallace AA, Clayton FC, Bohn D, Leonard YM, Detwiler TJ Jr, Lynch JJ Jr, Yan Y, Chen Z, Kuo L, Gardell SJ, Shafer JA, Vacca JP (2003) Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. development of an orally bioavailable series containing P1 and P3 pyridines. J Med Chem 46:461–473.
296. Reiner JE, Siev DV, Araldi G-L, Cui JJ, Ho JZ, Reddy KM, Mamedova L, Vu PH, Lee K-SS, Minami NK, Gibson TS, Anderson SM, Bradbury AE, Nolan TG, Semple JE (2002) Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates. Bioorg Med Chem Lett 12:1203–1208.
297. Cui JJ, Araldi G-L, Reiner JE, Reddy KM, Kemp SJ, Ho JZ, Siev DV, Mamedova L, Gibson TS, Gaudette JA, Minami NK, Anderson SM, Bradbury AE, Nolan TG, Semple JE (2002) Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates. Bioorg Med Chem Lett 12:2925–2930.
298. Zhou Q, Ruffoni A, Gianatassio R, Fujiwara Y, Sella E, Shabat D, Baran PS (2013) Direct synthesis of fluorinated heteroarylether bioisosteres. Angew Chem Int Ed 52:3949–3952.
299. Austin RP, Barton P, Bonnert RV, Brown RC, Cage PA, Cheshire DR, Davis AM, Dougall IG, Ince F, Pairaudeau G, Young A (2003) QSAR and the rational design of long-acting dual D2-receptor/β2-adrenoceptor agonists. J Med Chem 46:3210–3220.
300. Blake MI, Crespi HL, Katz JJ (1975) Studies with deuterated drugs. J Pharm Sci 64:367–391.
301. Yarnell AT (2009) Heavy-hydrogen drugs turn heads, again. Firms seek to improve drug candidates by selective deuterium substitution. Chem Eng News 87:36–39.
302. Shao L, Hewitt MC (2010) The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 23:398–404.
303. Harbeson SL, Tung RD (2011) Deuterium in drug discovery and development. Ann Rep Med Chem 46:403–417.
304. Katsnelson A (2013) Heavy drugs draw heavy interest from pharma backers. Nature Med 19:656.
305. El Tayar N, van de Waterbeemd H, Gryllaki M, Testa B, Trager WF (1984) The lipophilicity of deuterium atoms. A comparison of shake-flask and HPLC methods. Int J Pharmaceutics 19:271–281.
306. Turowski M, Yamakawa N, Meller J, Kimata K, Ikegami T, Hosoya K, Tanaka N, Thornton ER (2003) Deuterium isotope effects on hydrophobic interactions: the importance of dispersion interactions in the hydrophobic phase. J Am Chem Soc 125:13836–13849.
307. Kimata K, Hosoya K, Araki T, Tanaka N (1997) Direct chromatographic separation of racemates on the basis of isotopic chirality. Anal Chem 69:2610–2612.
308. Perrin CL, Ohta BK, Kuperman J (2003) β-Deuterium isotope effects on amine basicity, “inductive” and stereochemical. J Am Chem Soc 125:15008–15009.
309. Perrin CL, Ohta BK, Kuperman J, Liberman J, Erdélyi M (2005) Stereochemistry of β-deuterium isotope effects on amine basicity. J Am Chem Soc 127:9641–9647.
310. Perrin CL, Dong Y (2008) Nonadditivity of secondary deuterium isotope effects on basicity of triethylamine. J Am Chem Soc 130:11143–11148.
311. Perrin CL, Dong Y (2007) Secondary deuterium isotope effects on the acidity of carboxylic acids and phenols. J Am Chem Soc 129:4490–4497.
312. Foster AB (1984) Deuterium isotope effects in studies of drug metabolism. Trends Pharmacol Sci 5:524–527.
313. Nelson SD, Trager WF (2003) The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity. Drug Metab Disp 31:1481–1498.
314. Mutlib AE (2008) Application of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studies. Chem Res Toxicol 21:1672–1689.
315. Belleau B, Burba J, Pindell M, Reiffenstein J (1961) Effect of deuterium substitution in sympathomimetic amine on adrenergic responses. Science 133:102–104.
316. Westheimer FH (1961) The magnitude of the primary kinetic isotope effect for compounds of hydrogen and deuterium. Chem Rev 61:265–273.
317. Peng S, van der Donk WA (2003) An unusual isotope effect on substrate inhibition in the oxidation of arachidonic acid by lipoxygenase. J Am Chem Soc 125:8988–8989.
318. Gant TG, Sarshar S (2008) Substituted phenethylamines with serotonergic and/or norepinephrinergic activity. US Patent 7,456, 317, November 25, 2008.
319. Tung R (2007) Novel benzo-[D] [1,3]-dioxol derivatives. World Patent Application WO 2007/016,431, February 8th, 2007.
320. Murray M (2000) Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 1:67–84.
321. Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP 2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Disp 31:289–293.
322. Venkatakrishnan K, Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Disp 33:845–852.
323. Manley PW, Blasco F, Mestan J, Aichholz R (2013) The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74Bioorg Med Chem 21:3231–3239.
324. Shao L, Abolin C, Hewitt MC, Koch P, Varney M (2006) Derivatives of tramadol for increased duration of effect. Bioorg Med Chem Lett 16:691–694.
325. Velthuisen EJ, Baughman TM, Johns BA, Temelkoff DP, Weatherhead JG (2013) Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. Eur J Med Chem 63:202–212.
326. Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL (2009) In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem 52:7993–8001.
327. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT (2000) The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 169:102–113.
328. Zhu Y, Zhou J, Jiao B (2013) Deuterated clopidogrel analogues as a new generation of antiplatelet agents. ACS Med Chem Lett 4:349–352.
329. Laizure SC, Parker RB (2010) A comparison of the metabolism of clopidogrel and prasugrel. Expert Opin Drug Metab Toxicol 6:1417–1424.
330. Bains W, Tacke R (2003) Silicon chemistry as a novel source of chemical diversity in drug design. Curr Opin Drug Discov Dev 6:526–543.
331. Franz AK, Wilson SO (2013) Organosilicon molecules with medicinal applications. J Med Chem 56:388–405.
332. Tacke R, Popp F, Müller B, Theis B, Burschka C, Hamacher A, Kassack MU, Schepmann D, Wünsch B, Jurva U, Wellner E (2008) Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. ChemMedChem 3:152–164.
333. Subramanyam B, Woolf T, Castagnoli N Jr (1991) Studies on the in-vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4:123–128.
334. Johansson T, Weidolf L, Popp F, Tacke R, Jurva U (2010) In vitro metabolism of haloperidol and sila-haloperidol: new metabolic pathways resulting from carbon/silicon exchange. Drug Metab Disp 38:73–83.
335. Tanaka H, Shishido Y (2007) Synthesis of aromatic compounds containing a 1,1-dialkyl-2- trifluoromethyl group, a bioisostere of the tert-alkyl moiety. Bioorg Med Chem Lett 17:6079–6085.
336. Barnes-Seeman D, Jain M, Bell L, Ferreira S, Cohen S, Chen X-H, Amin J, Snodgrass B, Hatsis P (2013) Metabolically stable tert-butyl replacement. ACS Med Chem Lett 4:514–516.
337. Yu K-L, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJK, Dalterio RA, Zadjura L, Marino A, Dando S, D’Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA (2007) Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett 17:895–901.
338. Skuballa W, Schillinger E, C-St S, Vorbrüggen H (1986) Synthesis of a new chemically and metabolically stable prostacyclin analogue with high and long-lasting oral activity. J Med Chem 29:313–315.
339. Kim J-JP, Battaile KP (2002) Burning fat: the structural basis of fatty acid β-oxidation. Curr Opin Struct Biol 12:721–728.
340. Świzdor A, Panek A, Milecka-Tronina N, Kołek T (2012) Biotransformations utilizing β-oxidation cycle reactions in the synthesis of natural compounds and medicines. Int J Mol Sci 13:16514–16543.
341. Li C, Benet LZ, Grillo MP (2002) Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol 5:1309–1317.
342. Grillo MP (2011) Drug-S-acyl-glutathione thioesters: synthesis, bioanalytical properties, chemical reactivity, biological formation and degradation. Curr Drug Metab 12:229–244.
343. Darnell M, Weidolf L (2013) Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. Chem Res Toxicol. doi:10.1021/tx400183y
344. Ballatore C, Huryn DM, Smith AB III (2013) Carboxylic acid (bio)isosteres in drug design. Chem Med Chem 8:385–395.
345. Hamada Y, Kiso Y (2012) The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. Expert Opin Drug Discov 7:903–922.
346. Stachulski AV, Harding JR, Lindon JC, Maggs JL, Park BK, Wilson ID (2006) Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J Med Chem 49:6931–6945.
347. Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 31:367–395.
348. Baba A, Yoshioka T (2009) Structure–activity relationships for degradation reaction of 1-β-O-acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions. Chem Res Toxicol 22:158–172.
349. Baba A, Yoshioka T (2009) Structure–activity relationships for degradation reaction of 1-β-O-acyl glucuronides. Part 2: Electronic and steric descriptors predicting the reactivity of 1-β-O-acyl glucuronides derived from benzoic acids. Chem Res Toxicol 22:1559–1569.
350. Baba A, Yoshioka T (2009) Structure–activity relationships for degradation reaction of 1-β-O-acyl glucuronides. Part 3: Electronic and steric descriptors predicting the reactivity of aralkyl carboxylic acid 1-β-O-acyl glucuronides. Chem Res Toxicol 22:1998–2008.
351. Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, Okazaki O (2010) Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Disp 38:1857–1864.
352. Krogsgaard-Larsen P, Ebert B, Lund TM, Briiuner-Osbome H, Slok FA, Johansen TN, Brehm L, Madsen U (1996) Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure. Eur J Med Chem 31:515–537.
353. Pemberton N, Graden H, Evertsson E, Bratt E, Lepisto¨ M, Johannesson P, Svensson PH (2012) Synthesis and functionalization of cyclic sulfonimidamides: a novel chiral heterocyclic carboxylic acid bioisostere. ACS Med Chem Lett 3:574–578.
354. Petrillo E Jr, Ondetti M (1982) Angiotensin-converting enzyme inhibitors: medicinal chemistry and biological actions. Med Res Rev 2:1–41.
355. Ishak R, Abbas O (2013) Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects. Am J Clin Dermatol 14:223–233.
356. Narjes F, Koehler KF, Koch U, Gerlach B, Colarusso S, Steinkühler C, Brunetti M, Altamura S, De Francesco R, Matassa VG (2002) A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 12:701–704.
357. Erickson JA, McLoughlin JI (1995) Hydrogen bond donor properties of the difluoromethyl group. J Org Chem 60:1626–1631.
358. Albers HMHG, Ovaa H (2012) Chemical evolution of autotaxin inhibitors. Chem Rev 112:2593–2603.
359. Mutoh T, Rivera R, Chun J (2012) Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol 165:829–844.
360. Xu Y, Qian L, Pontsler AV, McIntyre TM, Prestwich GD (2004) Synthesis of difluoromethyl substituted lysophosphatidic acid analogues. Tetrahedron 60:43–49.
361. Xu Y, Prestwich GD (2002) Concise synthesis of acyl migration-blocked 1,1-difluorinated analogues of lysophosphatidic acid. J Org Chem 67:7158–7161.
362. Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, Yang Z, Zadjura LM, D’Arienzo CJ, DiGiugno PD, Gesenberg C, Yamanaka GA, Gong Y-F, Ho H-T, Fang H, Zhou N, McAuliffe BV, Eggers BJ, Fan L, Nowicka-Sans B, Dicker IB, Gao Q, Colonno RJ, Lin P-F, Meanwell NA, Kadow JF (2009) Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1- yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J Med Chem 52:7778–7787.
363. Kalgutkar AS, Griffith DA, Ryder T, Sun H, Miao Z, Bauman JN, Didiuk MT, Frederick KS, Zhao SX, Prakash C, Soglia JR, Bagley SW, Bechle BM, Kelley RM, Dirico K, Zawistoski M, Li J, Oliver R, Guzman-Perez A, Liu KKC, Walker DP, Benbow JW, Morris J (2010) Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chem Res Toxicol 23:1115–1126.
364. Southers JA, Bauman JN, Price DA, Humphries PS, Balan G, Sagal JF, Maurer TS, Zhang Y, Oliver R, Herr M, Healy DR, Li M, Kapinos B, Fate GD, Riccardi KA, Paralkar VM, Brown TA, Kalgutkar AS (2010) Metabolism-guided design of short-acting calcium-sensing receptor antagonists. ACS Med Chem Lett 1:219–223.
365. Hartz RA, Ahuja VT, Zhuo X, Mattson RJ, Denhart DJ, Deskus JA, Vrudhula VM, Pan S, Ditta JL, Shu Y-Z, Grace JE, Lentz KA, Lelas S, Li Y-W, Molski TF, Krishnananthan S, Wong H, Qian-Cutrone J, Schartman R, Denton R, Lodge NJ, Zaczek R, Macor JE, Bronson JJ (2009) A strategy to minimize reactive metabolite formation: discovery of (S)-4- (1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5- oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. J Med Chem 52:7653–7658.
366. Hartz RA, Ahuja VT, Schmitz WD, Molski TF, Mattson GK, Lodge NJ, Bronson JJ, Macor JE (2010) Synthesis and structure–activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. Bioorg Med Chem Lett 20:1890–1894.
367. Zhuo X, Hartz RA, Bronson JJ, Wong H, Ahuja VT, Vrudhula VM, Leet JE, Huang S, Macor JE, Shu Y-Z (2010) Comparative biotransformation of pyrazinone-containing corticotropinreleasing factor receptor-1 antagonists: minimizing the reactive metabolite formation. Drug Metab Disp 38:5–15.
368. Atwal KS, Rovnyak GC, Schwartz J, Moreland S, Hedberg A, Gougoutas JZ, Malley MM, Floyd DM (1990) Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxyaliccid esters as potent mimics of dihydropyridines. J Med Chem 33:1510–1515.
369. Atwal KS, Rovnyak GC, Kimball SD, Floyd DM, Moreland S, Swanson BN, Gougoutas JZ, Schwartz J, Smillie KM, Malley MF (1990) Dihydropyrimidine calcium channel blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxyalciicd esters as potent mimics of dihydropyridines. J Med Chem 33:2629–2635.
370. Atwal KS, Swanson BN, Unger SE, Floyd DM, Moreland S, Hedberg A, O’Reilly BC (1991) Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6- methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents. J Med Chem 34:806–811.
371. Rovnyak GC, Atwal KS, Hedberg A, Kimball SD, Moreland S, Gougoutas JZ, O’Reilly BC, Schwartz J, Malley MF (1992) Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents. J Med Chem 35:3254–3263.
372. Wood MR, Schirripa KM, Kim JJ, Wan B-L, Murphy KL, Ransom RW, Chang RSL, Tang C, Prueksaritanont T, Detwiler TJ, Hettrick LA, Landis ER, Leonard YM, Krueger JA, Lewis SD, Pettibone DJ, Freidinger RM, Bock MG (2006) Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists. J Med Chem 49:1231–1234.
373. Testa B, Pedretti A, Vistoli G (2012) Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today 17:549–560.
374. Testa B, Krämer SD (2007) The biochemistry of drug metabolism – an introduction Part 3. Reactions of hydrolysis and their enzymes. Chem Biodivers 4:2031–2122.
375. Testa B, Kra¨mer SD (2007) The biochemistry of drug metabolism – an introduction Part 2. Redox reactions and their enzymes. Chem Biodivers 4:257–405.
376. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650.
377. Peng HM, Raner GM, Vaz ADN, Coon MJ (1995) Oxidative cleavage of esters and amides to carbonyl products by cytochrome PArch Biochem Biophys 318:333–339.
378. Watjen F, Baker R, Engelstoff M, Herbert R, MacLeod A, Knight A, Merchant K, Moseley J, Saunders J, Swain CJ, Wong E, Springer JP (1989) Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines. J Med Chem 32:2282–2291.
379. Saunders J, Cassidy M, Freedman SB, Harley EA, Iversen LL, Kneen C, MacLeod AM, Merchant KJ, Snow RJ, Baker R (1990) Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. J Med Chem 33:1128–1138.
380. Krogsgaard-Larsen P, Falch E, Sauerberg P, Freedman SB, Lembøl HL, Meier E (1988) Bioisosteres of arecoline as novel CNS-active muscarinic agonists. Trends Pharmacol Sci Suppl:69–74.
381. Kim J, Ok T, Park C, So W, Jo M, Kim Y, Seo M, Lee D, Jo S, Ko Y, Choi I, Park Y, Yoon J, Kyeong Ju M, Ahn JY, Kim J, Han S-J, Kim T-H, Cechetto J, Nam J, Liuzzi M, Sommer P, No Z (2012) A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability. Bioorg Med Chem Lett 22:2522–2526.
382. Rajapakse HA, Nantermet PG, Selnick HG, Barrow JC, McGaughey GB, Munshi S, Lindsley SR, Young MB, Ngo PL, Holloway MK, Lai M-T, Espeseth AS, Shi X-P, Colussi D, Pietrak B, Crouthamel M-C, Tugusheva K, Huang Q, Xu M, Simon AJ, Kuo L, Hazuda DJ, Graham S, Vacca JP (2010) SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett 20:1885–1889.
383. Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ (2012) An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med Chem Lett 3:303–307.
384. Sun Z-Y, Asberom T, Bara T, Bennett C, Burnett D, Chu I, Clader J, Cohen-Williams M, Cole D, Czarniecki M, Durkin J, Gallo G, Greenlee W, Josien H, Huang X, Hyde L, Jones N, Kazakevich I, Li H, Liu X, Lee J, MacCoss M, Mandal MB, McCracken T, Nomeir A, Mazzola R, Palani A, Parker EM, Pissarnitski DA, Qin J, Song L, Terracina G, Vicarel M, Voigt J, Xu R, Zhang L, Zhang Q, Zhao Z, Zhu X, Zhu Z (2012) Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo. J Med Chem 55:489–502.
385. Valverde IE, Bauman A, Kluba CA, Vomstein S, Walter MA, Mindt TL (2013) 1,2,3- Triazoles as amide bond mimics: triazole scan yields protease-resistant peptidomimetics for tumor targeting. Angew Chem Int Ed 52:8957–8960.
386. Xia G, You X, Liu L, Liu H, Wang J, Shi Y, Li P, Xiong B, Liu X, Shen J (2013) Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Eur J Med Chem 62:1–10.
387. Staben ST, Blaquiere N, Tsui V, Kolesnikov A, Do S, Bradley EK, Dotson J, Goldsmith R, Heffron TP, Lesnick J, Lewis C, Murray J, Nonomiya J, Olivero AG, Pang J, Rouge L, Salphati L, Wei BQ, Wiesmann C, Wu P (2013) Cis-Amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase. Bioorg Med Chem Lett 23:897–901.
388. Taylor R, Mullaley A, Mullier GW (1990) Use of crystallographic data in searching for isosteric replacements: composite crystal-field environments of nitro and carbonyl groups. Pestic Sci 29:197–213.
389. Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble MEM, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J (2011) Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein–protein interaction: structure–activity studies leading to improved potency. J Med Chem 54:1233–1243.
390. Firestine SM, Davisson VJ (1993) A tight binding inhibitor of 5-aminoimidazole ribonucleotide carboxylase. J Med Chem 36:3484–3486.
391. Thorson JS, Chapman E, Schultz PG (1995) Analysis of hydrogen bonding strengths in proteins using unnatural amino acids. J Am Chem Soc 117:9361–9362.
392. Alston TA, Porter DJT, Bright HJ (1983) Enzyme inhibition by nitro and nitroso compounds. Acc Chem Res 16:418–424.
393. Julémont F, de Leval X, Michaux C, Damas J, Charlier C, Durant F, Pirotte B, Dogné J-M (2002) Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. J Med Chem 45:5182–5185.
394. Renard J-F, Arslan D, Garbacki N, Pirotte B, de Leval X (2009) Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. J Med Chem 52:5864–5871.
395. Gougoutas JZ, Ojala WH, Malley MF (1982) 3,4-bis(4-Chlorophenyl)sydnone. Cryst Struct Comm 11:1731–1736